Phage Therapy against IStaphylococcus aureus/I: Selection and Optimization of Production Protocols of Novel Broad-Spectrum ISilviavirus/I Phages

• Published in: Pharmaceutics 2022-09, Vol.14 (9)
• Main Authors: Kolenda, Camille, Medina, Mathieu, Bonhomme, Mélanie, Laumay, Floriane, Roussel-Gaillard, Tiphaine, Ma, Tristan, Anne, Pirot, Fabrice, Ferry, Tristan, Laurent, Frédéric
• Format: Article
• Language: English
• Subjects: Analysis; Antibiotics; Care and treatment; Complications and side effects; Dosage and administration; Drug resistance in microorganisms; Patient outcomes; Phage therapy; Prevention; Staphylococcal infections; Virulence (Microbiology)
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14091885

Background: Phage therapy a promising antimicrobial strategy to address antimicrobial resistance for infections caused by the major human pathogen Staphylococcus aureus. Development of therapeutic phages for human use should follow pharmaceutical standards, including selection of strictly lytic bacteriophages with high therapeutic potential and optimization of their production process. Results: Here, we describe three novel Silviavirus phages active against 82% of a large collection of strains (n = 150) representative of various methicillin-susceptible and -resistant S. aureus clones circulating worldwide. We also investigated the optimization of the efficiency and safety of phage amplification protocols. To do so, we selected a well-characterized bacterial strain in order to (i) maximize phage production yields, reaching phage titres of 10[sup.11] PFU/mL in only 4 h; and (ii) facilitate phage purity while minimizing the risk of the presence of contaminants originating from the bacterial host; i.e., secreted virulence factors or induced temperate phages. Conclusions: In sum, we propose a quality-by-design approach for the amplification of broad-spectrum anti-S. aureus phages, facilitating the subsequent steps of the manufacturing process; namely, purification and quality control.